Z nami tylko najlepsze analizy!

Referencje - LIT

Poniżej znajdują się referencje do opracowania dotyczącego Litu w raporcie o pierwiastkach.


1. ^ Jump up to: a b "Lithium brands". Drugs.com. Archived from the original on 5 April 2017. Retrieved 4 April 2017. 
2. ^ Jump up to: a b c d e f g h i j k l m n o p "Lithium Salts". The American Society of Health-System Pharmacists. Archived from the original on 2015-12-08. Retrieved Dec 1, 2015. 
3. Jump up ^ Baldessarini, Ross J; Tondo, Leonardo; Davis, Paula; Pompili, Maurizio; Goodwin, Frederick K; Hennen, John (2006). "Decreased risk of suicides and attempts during long-term lithium treatment: A meta-analytic review". Bipolar Disorders. 8 (5p2): 625–39. PMID 17042835. doi:10.1111/j.1399-5618.2006.00344.x. 
4. ^ Jump up to: a b "Lithium use while Breastfeeding". LactMed. 2015-03-10. Archived from the original on 8 December 2015. Retrieved 1 December 2015. 
5. ^ Jump up to: a b Sneader, Walter (2005). Drug discovery : a history (Rev. and updated ed.). Chichester: Wiley. p. 63. ISBN 9780471899792. Archived from the original on 2017-09-08. 
6. Jump up ^ "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016. 
7. Jump up ^ "Lithium Carbonate". International Drug Price Indicator Guide. Retrieved 1 December 2015. 
8. Jump up ^ Cipriani, A.; Hawton, K.; Stockton, S.; Geddes, JR. (2013). "Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis.". BMJ. 346: f3646. PMID 23814104. doi:10.1136/bmj.f3646. 
9. Jump up ^ Müller-Oerlinghausen, B; Berghöfer, A; Ahrens, B (2003). "The Antisuicidal and Mortality-Reducing Effect of Lithium Prophylaxis: Consequences for Guidelines in Clinical Psychiatry". Canadian Journal of Psychiatry. 48 (7): 433–9. PMID 12971012. Archived from the original on 2011-07-25. 
10. Jump up ^ Kovacsics, Colleen E.; Gottesman, Irving I.; Gould, Todd D. (2009). "Lithium's Antisuicidal Efficacy: Elucidation of Neurobiological Targets Using Endophenotype Strategies". Annual Review of Pharmacology and Toxicology. 49: 175–198. PMID 18834309. doi:10.1146/annurev.pharmtox.011008.145557. 
11. Jump up ^ Semple, David "Oxford Hand Book of Psychiatry" Oxford Press. 2005.[page needed]
12. Jump up ^ Rosenberg, J.; Salzman, C. (2007). "Update: New uses for lithium and anticonvulsants". CNS spectrums. 12 (11): 831–841. PMID 17984856. 
13. Jump up ^ Frye, M. A.; Salloum, I. M. (2006). "Bipolar disorder and comorbid alcoholism: Prevalence rate and treatment considerations". Bipolar Disorders. 8 (6): 677–685. PMID 17156154. doi:10.1111/j.1399-5618.2006.00370.x. 
14. Jump up ^ Vornik, L.; Brown, E. (2006). "Management of comorbid bipolar disorder and substance abuse". The Journal of Clinical Psychiatry. 67 Suppl 7: 24–30. PMID 16961421. 
15. Jump up ^ Ohgami, H; Terao, T; Shiotsuki, I; Ishii, N; Iwata, N (2009). "Lithium levels in drinking water and risk of suicide". The British Journal of Psychiatry. 194 (5): 464–5; discussion 446. PMID 19407280. doi:10.1192/bjp.bp.108.055798. 
16. Jump up ^ Gonzalez, R; Bernstein, I; Suppes, T (2008). "An investigation of water lithium concentrations and rates of violent acts in 11 Texas counties: Can an association be easily shown?". The Journal of Clinical Psychiatry. 69 (2): 325–6. PMID 18363457. doi:10.4088/jcp.v69n0221a. 
17. Jump up ^ Kapusta, ND; Mossaheb, N; Etzersdorfer, E; Hlavin, G; Thau, K; Willeit, M; Praschak-Rieder, N; Sonneck, G; Leithner-Dziubas, K (2011). "Lithium in drinking water and suicide mortality". The British Journal of Psychiatry. 198 (5): 346–350. PMID 21525518. doi:10.1192/bjp.bp.110.091041. 
18. Jump up ^ Healy D. 2005. Psychiatric Drugs Explained. 4th ed. Churchhill Livingstone: London.[page needed]
19. Jump up ^ Amdisen A. (1978). "Clinical and serum level monitoring in lithium therapy and lithium intoxication". J. Anal. Toxicol. 2: 193–202. doi:10.1093/jat/2.5.193. 
20. Jump up ^ R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 851–854.
21. Jump up ^ The UK Electronic Medical Compendium recommends 0.4–0.8 mmol/l plasma lithium level in adults for prophylaxis of recurrent affective bipolar manic-depressive illness Camcolit 250 mg Lithium Carbonate Archived 2016-03-04 at the Wayback Machine. Revision 2 December 2010, Retrieved 5 May 2011
22. Jump up ^ One study (Solomon, D.; Ristow, W.; Keller, M.; Kane, J.; Gelenberg, A.; Rosenbaum, J.; Warshaw, M. (1996). "Serum lithium levels and psychosocial function in patients with bipolar I disorder". The American Journal of Psychiatry. 153 (10): 1301–1307. PMID 8831438. ) concluded a "low" dose of 0.4–0.6 mmol/L serum lithium treatment for patients with bipolar 1 disorder had less side effects, but a higher rate of relapse, than a "standard" dose of 0.8–1.0 mmol/l. However, a reanalysis of the same experimental data (Perlis, R.; Sachs, G.; Lafer, B.; Otto, M.; Faraone, S.; Kane, J.; Rosenbaum, J. (2002). "Effect of abrupt change from standard to low serum levels of lithium: A reanalysis of double-blind lithium maintenance data". The American Journal of Psychiatry. 159 (7): 1155–1159. PMID 12091193. doi:10.1176/appi.ajp.159.7.1155. ) concluded the higher rate of relapse for the "low" dose was due to abrupt changes in the lithium serum levels[improper synthesis?]
23. ^ Jump up to: a b c Truven Health Analytics, Inc. DrugPoint® System (Internet) [cited 7 October 2013]. Greenwood Village, CO: Thomsen Healthcare; 2013.
24. Jump up ^ Australian Medicines Handbook. Adelaide: Australian Medicines Handbook Pty Ltd. 2013. ISBN 9780980579086. 
25. Jump up ^ Joint Formulary Committee (2013). British National Formulary (BNF) 65. London: Pharmaceutical Press. pp. 240–242. ISBN 9780857110848. 
26. Jump up ^ "lithium (Rx) - Eskalith, Lithobid". Medscape. WebMD. Archived from the original on 4 December 2013. Retrieved 7 October 2013. 
27. Jump up ^ "LITHOBID (lithium carbonate) tablet, film coated, extended release [NOVEN THERAPEUTICS, LLC]". DailyMed. National Library of Medicine. Archived from the original on 5 October 2013. Retrieved 7 October 2013. 
28. Jump up ^ "PRODUCT INFORMATION LITHICARB Lithium carbonate". TGA eBusiness Services. Aspen Pharmacare Australia Pty Ltd. Archived from the original on 22 March 2017. Retrieved 7 October 2013. 
29. ^ Jump up to: a b Bedford, JJ; Weggery, S; Ellis, G; McDonald, FJ; Joyce, PR; Leader, JP; Walker, RJ (Sep 2008). "Lithium-induced Nephrogenic Diabetes Insipidus: Renal Effects of Amiloride". Clin J Am Soc Nephrol. 3: 1324–1331. doi:10.2215/CJN.01640408. 
30. ^ Jump up to: a b Aiff, H; Attman, P-O; Aurel, M; Bendz, H; Ramsauer, B; Schon, S; Svedlund, J (May 2015). "Effects of 10 to 30 years of lithium treatment on kidney function". J Psychopharmacol. 29: 608–614. doi:10.1177/0269881115573808. 
31. ^ Jump up to: a b Safe and effective use of lithium Archived 2013-07-25 at the Wayback Machine. Australian Prescriber
32. Jump up ^ Sperner-Unterweger, Barbara; W. Wolfgang Fleischhacker; Wolfgang P. Kaschka (2001). Psychoneuroimmunology. Karger Publishers. p. 22. ISBN 3-8055-7262-X. 
33. Jump up ^ Silver, M; Factor, S (2015). "Chapter 12: VPA, lithium, amiodarone, and other non-DA". In Friedman, J. Medication-Induced Movement Disorders. Cambridge University Press. pp. 131–140. ISBN 978-1-107-06600-7. 
34. Jump up ^ McLarty DG, O'Boyle JH, Spencer CA, Ratcliffe JG (1975). "Effect of lithium on hypothalamic-pituitary-thyroid function in patients with affective disorders.". Br Med J. 3: 623–6. PMC 1674449 . PMID 809083. doi:10.1136/bmj.3.5984.623. 
35. Jump up ^ Wetzels, JF; Van Bergeijk, JD; Hoitsma, AJ; Huysmans, FT; Koene, RA (1989). "Triamterene increases lithium excretion in healthy subjects: Evidence for lithium transport in the cortical collecting tubule". Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 4 (11): 939–42. PMID 2516883. 
36. Jump up ^ Keshavan, Matcheri S.; John S. Kennedy (2001). Drug-induced dysfunction in psychiatry. Taylor & Francis. p. 305. ISBN 0-89116-961-X. 
37. Jump up ^ Side Effects – Lithium / Various Brand Names – Bipolar Disorder Medications Archived 2007-03-03 at the Wayback Machine.
38. Jump up ^ Nutrition Articles – The Relationship between Weight Gain and Medications for Depression and Seizures Archived 2007-02-19 at the Wayback Machine.
39. Jump up ^ Safer lithium therapy Archived 2010-01-30 at the Wayback Machine.. NHS National Patient Safety Agency. Issue date: 1 December 2009
40. Jump up ^ Bendz, Hans; Schön, Staffan; Attman, Per-Ola; Aurell, Mattias (1 February 2010). "Renal failure occurs in chronic lithium treatment but is uncommon". Kidney International. 77 (3): 219–24. PMID 19940841. doi:10.1038/ki.2009.433. 
41. Jump up ^ Shepard, TH.; Brent, RL.; Friedman, JM.; Jones, KL.; Miller, RK.; Moore, CA.; Polifka, JE. (2002). "Update on new developments in the study of human teratogens". Teratology. 65 (4): 153–61. PMID 11948561. doi:10.1002/tera.10032. 
42. ^ Jump up to: a b Yacobi, S; Ornoy, A (2008). "Is lithium a real teratogen? What can we conclude from the prospective versus retrospective studies? A review". The Israel Journal of Psychiatry and Related Sciences. 45 (2): 95–106. PMID 18982835. 
43. Jump up ^ Montouris, G (2003). "Gabapentin exposure in human pregnancy: Results from the Gabapentin Pregnancy Registry". Epilepsy & behavior : E&B. 4 (3): 310–7. PMID 12791334. doi:10.1016/S1525-5050(03)00110-0. 
44. Jump up ^ Weinstock, L; Cohen, LS; Bailey, JW; Blatman, R; Rosenbaum, JF (2001). "Obstetrical and neonatal outcome following clonazepam use during pregnancy: A case series". Psychotherapy and psychosomatics. 70 (3): 158–62. PMID 11340418. doi:10.1159/000056242. 
45. Jump up ^ "Archived copy". Archived from the original on 2016-10-25. Retrieved 2016-05-25. 
46. Jump up ^ Thomsen, Klaus; Shirley, David G. (2006-04-01). "A hypothesis linking sodium and lithium reabsorption in the distal nephron". Nephrology Dialysis Transplantation. 21 (4): 869–880. ISSN 0931-0509. PMID 16410274. doi:10.1093/ndt/gfk029. 
47. Jump up ^ Gitlin, M (Mar 1999). "Lithium and the kidney: an updated review.". Drug Saf. 20: 231–243. PMID 10221853. doi:10.2165/00002018-199920030-00004. 
48. Jump up ^ Nielsen, J; Kwon, TH; Christensen, BM; Frokiaer, J; Nielsen, S (May 2008). "Dysregulation of renal aquaporins and epithelial sodium channel in lithium-induced nephrogenic diabetes insipidus". Semin. Nephrol. 28: 227–244. doi:10.1016/j.semnephrol.2008.03.002. 
49. ^ Jump up to: a b Alexander, MP; Farag, YM; Mittal, BV; Rennke, HG; Singh, AK (Jan 2008). "Lithium toxicity: a double-edged sword". Kidney Int. 73: 233–237. PMID 17943083. doi:10.1038/sj.ki.5002578. 
50. Jump up ^ Boton, R; Gaviria, M; Battlle, DC (Nov 1987). "Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy". Am J Kidney Dis. 10: 329–345. PMID 3314489. doi:10.1016/s0272-6386(87)80098-7. 
51. Jump up ^ Timmer, RT; Sands, JM (Mar 1999). "Lithium intoxication". J Am Soc Nephrol. 10: 666–674. PMID 10073618. 
52. Jump up ^ Sands, JM; Bichet, DG (Feb 2006). "Nephrogenic diabetes insipidus". Ann Intern Med. 144: 186–194. PMID 16461963. doi:10.7326/0003-4819-144-3-200602070-00007. 
53. Jump up ^ Thompson, CJ; France, AJ; Baylis, PH (Feb 1997). "Persistent nephrogenic diabetes insipidus following lithium therapy". Scott Med J. 42: 16–17. PMID 9226773. 
54. Jump up ^ Stone, KA (Jan 1999). "Lithium-induced nephrogenic diabetes insipidus". J Am Board Fam Pract. 12: 43–47. PMID 10050642. doi:10.3122/15572625-12-1-43. 
55. Jump up ^ Garofeanu, CG; Weir, M; Rosas-Arellano, MP; Garg, AX; Clark, WF (Apr 2005). "Causes of reversible nephrogenic diabetes insipidus: a systematic review". Am J Kidney Dis. 45: 626–637. PMID 15806465. doi:10.1053/j.ajkd.2005.01.008. 
56. Jump up ^ Presne, C; Fakhouri, F; Noel, L-H; Stengel, B; Even, C; Kreis, H; Mignon, F; Grunfeld, J-P (Aug 2003). "Lithium-induced nephropathy: Rate of progression and prognostic factors". Kidney Int. 64: 585–592. PMID 12846754. doi:10.1046/j.1523-1755.2003.00096.x. 
57. Jump up ^ "Lithium". WebMD. Archived from the original on 2 November 2014. Retrieved 1 November 2014. 
58. ^ Jump up to: a b c Finley, PR (February 1996). "Lithium and angiotensin-converting enzyme inhibitors: evaluation of a potential interaction". J Clin Psychopharmacol. 16 (1): 68–71. PMID 8834421. doi:10.1097/00004714-199602000-00011. 
59. Jump up ^ Oruch, R (October 5, 2014). "Lithium: a review of pharmacology, clinical uses, and toxicity". Eur J Pharmacol. 740 (740): 464–73. PMID 24991789. doi:10.1016/j.ejphar.2014.06.042. 
60. Jump up ^ Brian K. Alldredge; et al., eds. (2013). Applied Therapeutics: The Clinical Use of Drugs (10th ed.). Baltimore: Wolters Kluwer Health/Lippincott Williams & Wilkins. p. 1991. ISBN 978-1609137137. CS1 maint: Explicit use of et al. (link)
61. Jump up ^ Boyer, EW. "Serotonin syndrome". UpToDate. Wolters Kluwer. Archived from the original on 16 December 2013. Retrieved 8 October 2013. 
62. Jump up ^ Wijdicks, EFM. "Neuroleptic malignant syndrome". UpToDate. Wolters Kluwer. Archived from the original on 23 October 2013. Retrieved 8 October 2013. 
63. Jump up ^ Case reports: (Sandyk, R.; Hurwitz, M. D. (1983). "Toxic irreversible encephalopathy induced by lithium carbonate and haloperidol. A report of 2 cases". South African medical journal. 64 (22): 875–876. PMID 6415823. )(Gille, M.; Ghariani, S.; Piéret, F.; Delbecq, J.; Depré, A.; Saussu, F.; De Barsy, T. (1997). "Acute encephalomyopathy and persistent cerebellar syndrome after lithium salt and haloperidol poisoning". Revue neurologique. 153 (4): 268–270. PMID 9296146. )
64. Jump up ^ Emilien, G; Maloteaux, J (1996). "Lithium neurotoxicity at low therapeutic doses". Acta Neurol Belg. 96: 281–293. PMID 9008777. 
65. Jump up ^ Netto, I; Phutane, V (2012). "Reversible lithium neurotoxicity: review of the literature". Prim Care Companion CNS Disord. 14 (1). doi:10.4088/PCC.11r01197. 
66. Jump up ^ Gelder, M., Mayou, R. and Geddes, J. 2005. Psychiatry. 3rd ed. New York: Oxford. pp249.
67. Jump up ^ Adityanjee; Munshi, Thampy (2005). "The syndrome of irreversible lithium-effectuated neurotoxicity.". Clinical Neuropharmacology. 28 (1): 38–49. PMID 15714160. doi:10.1097/01.wnf.0000150871.52253.b7. 
68. ^ Jump up to: a b Brunton, L; Chabner, B; Knollman, B (2010). Goodman and Gilman's The Pharmacological Basis of Therapeutics (12th ed.). New York: McGraw-Hill Professional. ISBN 978-0-07-162442-8. 
69. Jump up ^ Massot, O.; Rousselle, J. C.; Fillion, M. P.; Januel, D.; Plantefol, M.; Fillion, G. (1999). "5-HT1B Receptors: A Novel Target for Lithium Possible Involvement in Mood Disorders". Neuropsychopharmacology. 21 (4): 530–541. PMID 10481837. doi:10.1016/S0893-133X(99)00042-1. 
70. Jump up ^ Scheuch, K.; Höltje, M.; Budde, H.; Lautenschlager, M.; Heinz, A.; Ahnert-Hilger, G.; Priller, J. (2010). "Lithium modulates tryptophan hydroxylase 2 gene expression and serotonin release in primary cultures of serotonergic raphe neurons". Brain Research. 1307: 14–21. PMID 19840776. doi:10.1016/j.brainres.2009.10.027. 
71. Jump up ^ York JD, et al. (1995). "Definition of a metal-dependent/Li+-inhibited phosphomonoesterase protein family based upon a conserved three-dimensional core structure". Proc. Natl. Acad. Sci. U.S.A. 92: 5149–5153. PMC 41866 . PMID 7761465. doi:10.1073/pnas.92.11.5149. 
72. Jump up ^ Yenush (2000). "A novel target of lithium therapy". FEBS Lett. 467: 321–325. doi:10.1016/s0014-5793(00)01183-2. 
73. Jump up ^ Toledano E, et al. (2012). "3'-5' phosphoadenosine phosphate is an inhibitor of PARP-1 and a potential mediator of the lithium-dependent inhibition of PARP-1 in vivo". Biochem J. 443 (2): 485–90. PMC 3316155 . PMID 22240080. doi:10.1042/BJ20111057. 
74. Jump up ^ Ghasemi M, Sadeghipour H, Mosleh A, Sadeghipour HR, Mani AR, Dehpour AR; Sadeghipour; Mosleh; Sadeghipour; Mani; Dehpour (May 2008). "Nitric oxide involvement in the antidepressant-like effects of acute lithium administration in the mouse forced swimming test". Eur Neuropsychopharmacol. 18 (5): 323–32. PMID 17728109. doi:10.1016/j.euroneuro.2007.07.011. CS1 maint: Multiple names: authors list (link)
75. Jump up ^ Ghasemi M, Sadeghipour H, Poorheidari G, Dehpour AR; Sadeghipour; Poorheidari; Dehpour (June 2009). "A role for nitrergic system in the antidepressant-like effects of chronic lithium treatment in the mouse forced swimming test". Behav. Brain Res. 200 (1): 76–82. PMID 19166880. doi:10.1016/j.bbr.2008.12.032. CS1 maint: Multiple names: authors list (link)
76. Jump up ^ Ghasemi M, Raza M, Dehpour AR; Raza; Dehpour (April 2010). "NMDA receptor antagonists augment antidepressant-like effects of lithium in the mouse forced swimming test". J. Psychopharmacol. (Oxford). 24 (4): 585–94. PMID 19351802. doi:10.1177/0269881109104845. CS1 maint: Multiple names: authors list (link)
77. ^ Jump up to: a b c d e f g h i j k l m n o p Malhi GS (2013). "Potential mechanisms of action of lithium in bipolar disorder. Current understanding.". CNS Drugs. 27 (2): 135–53. PMID 23371914. doi:10.1007/s40263-013-0039-0. 
78. Jump up ^ Nicholas J. Birch. "Lithium and the Cell: Pharmacology and Biochemistry". Archived from the original on 2017-02-17. 
79. Jump up ^ Einat H, Kofman O, Itkin O, Lewitan RJ, Belmaker RH; Kofman; Itkin; Lewitan; Belmaker (1998). "Augmentation of lithium's behavioral effect by inositol uptake inhibitors". J Neural Transm. 105 (1): 31–8. PMID 9588758. doi:10.1007/s007020050035. CS1 maint: Multiple names: authors list (link)
80. Jump up ^ Jope RS (1999). "Anti-bipolar therapy: mechanism of action of lithium". Mol. Psychiatry. 4 (2): 117–128. PMID 10208444. doi:10.1038/sj.mp.4000494. 
81. Jump up ^ Wallace, James (Mar 2014). "Calcium dysregulation, and lithium treatment to forestall Alzheimer's disease - a merging of hypotheses". Cell Calcium. 55 (3): 175–181. PMID 24636273. doi:10.1016/j.ceca.2014.02.005. 
82. ^ Jump up to: a b c Marmol, F. (2008). "Lithium: Bipolar disorder and neurodegenerative diseases Possible cellular mechanisms of the therapeutic effects of lithium". Progress in Neuro-Psychopharmacology and Biological Psychiatry. 32 (8): 1761–1771. PMID 18789369. doi:10.1016/j.pnpbp.2008.08.012. 
83. Jump up ^ Lenox, RH; Watson, DG (1994). "Lithium and the brain: a psychopharmacological strategy to a molecular basis for manic depressive illness". Clinical Chemistry. 40 (2): 309–14. PMID 8313612. 
84. Jump up ^ Mitchell, PB; Hadzi-Pavlovic, D (2000). "Lithium treatment for bipolar disorder" (PDF). Bulletin of the World Health Organization. 78 (4): 515–7. PMC 2560742 . PMID 10885179. 
85. Jump up ^ Greenfield, Susan: "Brain Power: Working out the Human Mind", page 91. Element Books Limited, 1999
86. Jump up ^ Shorter E (2009). "The history of lithium therapy". Bipolar Disorders. 11: 4–9. PMC 3712976 . PMID 19538681. doi:10.1111/j.1399-5618.2009.00706.x. 
87. Jump up ^ Cade J. F. J. (1949). "Lithium salts in the treatment of psychotic excitement" (PDF). Medical Journal of Australia. 2 (10dfbnm): 349–52. PMID 18142718. Archived (PDF) from the original on 2006-05-25. 
88. Jump up ^ P. B. Mitchell, D. Hadzi-Pavlovic; Hadzi-Pavlovic (2000). "Lithium treatment for bipolar disorder" (PDF). Bulletin of the World Health Organization. 78 (4): 515–7. PMC 2560742 . PMID 10885179. Archived (PDF) from the original on 2006-05-25. 
89. Jump up ^ Agassi, Tirzah (1996-03-12). "Sting is now older, wiser and duller". The Jerusalem Post. Archived from the original on 2012-05-13. Retrieved 2009-06-25. 
90. Jump up ^ "7 UP: The Making of a Legend". Cadbury Schweppes: America's Beverages.
91. Jump up ^ "Urban Legends Reference Pages: 7Up". Retrieved 13 November 2007. 
92. Jump up ^ anonymous (13 July 1950). "ISALLY'S (ad)". Painesville Telegraph. Retrieved 8 September 2013. 
93. Jump up ^ Nieper HA (1973). "The clinical applications of lithium orotate. A two years study". Agressologie. 14 (6): 407–11. PMID 4607169. 
94. Jump up ^ Forlenza, OV; de Paula, VJ; Machado-Vieira, R; Diniz, BS; Gattaz, WF (1 May 2012). "Does lithium prevent Alzheimer's disease?". Drugs & aging. 29 (5): 335–42. PMID 22500970. doi:10.2165/11599180-000000000-00000. 
95. Jump up ^ Ludolph, AC; Brettschneider, J; Weishaupt, JH (October 2012). "Amyotrophic lateral sclerosis.". Current Opinion in Neurology. 25 (5): 530–5. PMID 22918486. doi:10.1097/WCO.0b013e328356d328. 

Add comment


Security code
Refresh